|
|
||||||||
Departments of Neurology and Psychiatry, Columbia University, College of Physicians and Surgeons, New York, NY; and the Departments of Psychiatry and Neurologyy, Massachusetts General Hospital, Division on Aging, Harvard Medical School, Boston, MA.
Physostigmine caused myoclonus in two patients with Alzheimer's disease during a clinical trial. Neither patient had myoclonus before or after physostigmine treatment. We hypothesize that physostigmine reduced the sensitivity of the remaining muscarinic receptors in these two patients, altering the interaction between cholinergic and either serotoninergic or dopaminergic neurotransmitter systems.
Address correspondence and reprint requests to Dr. Mayeux. Neurological Institute, 710 West 168th Street, New York, NY 10032.
Supported in part by public health grants (PO1-AG-04953, AG-05433) and the Charles S. Roberston Memorial Gift for Research in Alzheimer's Disease.
Received April 4, 1986. Accepted for publication May 15, 1986.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |